Novo Nordisk A/S (NVO)
Data as of September 4, 2026 · Drug Manufacturers - General
Stockbruh grade: Mixed 3/5 metrics rated Sunny
What does Novo Nordisk A/S do?
Novo Nordisk is a global healthcare company that specializes in developing pharmaceutical products to tackle diabetes, obesity, and other chronic diseases. 🌍 With its headquarters in Bagsvaerd, Denmark 🇩🇰, Novo Nordisk is on a mission to improve the lives of people worldwide. Join them in their quest for a healthier future! 💪💊.
Key Numbers
| Metric | Rating | What it means |
|---|
| Returns (5Y) | ⛈️ Weak | 5-year price performance |
| Profitability | ☀️ Strong | Net margin & return on equity |
| Growth | ☀️ Strong | Revenue & earnings trend |
| Earnings | ☀️ Strong | EPS vs analyst expectations |
| Cash & Debt | ⛈️ Weak | Balance sheet strength |
| Price | $47.51 | Market Cap | — |
| Exchange | New York Stock Exchange | | |
Plain-English Analysis
What's it worth?
Returns have been below average recently — worth reviewing valuation carefully before investing. Sign up free to see the full Stockbruh valuation breakdown.
How the business works
Novo Nordisk is a global healthcare company that specializes in developing pharmaceutical products to tackle diabetes, obesity, and other chronic diseases. 🌍 With its headquarters in Bagsvaerd, Denmark 🇩🇰, Novo Nordisk is on a mission to improve the lives of people worldwide. Sign up free for competitor and revenue breakdown ↗
Are they building the future?
Revenue and earnings are trending upward — Novo Nordisk A/S appears to be growing. Sign up free for the full growth analysis including year-over-year comparisons and R&D investment data.
What's ahead?
Recent earnings have been strong, meeting or beating analyst expectations. Sign up free for earnings history, EPS trends, and what analysts are forecasting next.